Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi Success As Global Player May Hinge on Obesity Drug In U.S., Analysts Say

This article was originally published in PharmAsia News

Executive Summary

TOKYO - In a bid to be recognized as a global player, mid-size pharmacuetical outfit Shionogi & Co. has been preparing to launch a few new drugs, including the anti-obesity drug S-2367 (velneperit), but analysts say it's too early to determine whether Shionogi can be successful overseas

You may also be interested in...



Shionogi To Divest Contract Manufacturer To Focus On Prescription Business

Japanese firm's goal is to consolidate resources to enhance it's prescription drug pipeline, maximize Crestor (rosuvastatin) product value, and strengthen domestic marketing and overseas expansion.

Shionogi To Divest Contract Manufacturer To Focus On Prescription Business

Japanese firm's goal is to consolidate resources to enhance it's prescription drug pipeline, maximize Crestor (rosuvastatin) product value, and strengthen domestic marketing and overseas expansion.

Shionogi To Divest Contract Manufacturer To Focus On Prescription Business

Osaka-based Shionogi's board of directors agreed to transfer wholly owned Bushu Pharmaceuticals to private investment fund TMC BUYOUT1, a subsidiary of Tokio Marine Capital beginning March 31. Bushu is the second-largest pharmaceutical contract manufacturer in Japan

Related Content

UsernamePublicRestriction

Register

SC073140

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel